Welcome to our dedicated page for Bone Biologics SEC filings (Ticker: BBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bone Biologics Corp filings document regulatory disclosures for a clinical-stage orthobiologic developer focused on rhNELL-1 and NB1 in spine fusion markets. Current reports on Form 8-K include Regulation FD updates on corporate, scientific, and operational milestones, along with exhibits tied to public communications.
The company’s filings also cover capital-structure activity, including common stock, warrants, shelf registration statements on Form S-3, prospectus supplements, and at-the-market offering arrangements. These disclosures describe financing tools, securities covered by registration documents, legal opinions, and related material-event reporting.
Bone Biologics Corp (BBLG) reports a Nasdaq bid‑price deficiency notice after its common stock closed below $1 per share for the last 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days, until March 9, 2027, to regain compliance by achieving a closing bid of at least $1 per share for a minimum of 10 consecutive business days.
If compliance is not regained by March 9, 2027, the company may qualify for a second 180‑day period if it meets certain other Nasdaq Capital Market standards and notifies Nasdaq of its intent to cure the deficiency. Failure to comply could lead to delisting, subject to an appeal. The company states it will monitor its share price and intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting, which its board may use to attempt to increase the share price and restore compliance. The notice has no immediate effect on the current Nasdaq listing.
Bone Biologics Corporation (BBLG) is asking stockholders at the September 28, 2026 annual meeting to elect four directors, approve executive compensation on an advisory basis, and ratify Weinberg & Company, P.A. as independent auditor for 2026.
The company also seeks approval under Nasdaq Listing Rule 5635(d) for the potential issuance of up to 4,352,115 shares of common stock underlying warrants issued in a July 7, 2026 private placement and to the placement agent. As of August 6, 2026, common shares outstanding were 2,011,057. The private placement provided approximately $2.7 million of net proceeds, with up to approximately $6.0 million of additional gross proceeds possible if the Common Warrants are fully exercised for cash.
Stockholders are further asked to authorize a reverse stock split of the common stock within a range of 1‑for‑2 to 1‑for‑10, at the Board’s discretion and without reducing the 100,000,000 authorized shares, and to approve potential adjournment of the meeting if needed to secure sufficient votes or a quorum.
Bone Biologics Corporation (BBLG) is asking stockholders to vote at the 2026 annual meeting, rescheduled to September 28, 2026, on a broad slate of governance and financing items. Routine items include electing four directors, an advisory say‑on‑pay vote, and ratification of Weinberg & Company, P.A. as independent auditor for 2026.
More strategically, BBLG seeks approval under Nasdaq Listing Rule 5635(d) to permit issuance of up to 4,352,115 shares of common stock upon exercise of pre‑funded, Series F, Series G and placement agent warrants from a July 7, 2026 private placement. That financing brought net proceeds of about $2.7 million, with an additional approximately $6.0 million of potential gross proceeds if the common warrants are fully exercised for cash.
The company also requests authority to implement, at the Board’s discretion within one year, a reverse stock split of the common stock in a range of 1‑for‑2 to 1‑for‑10 without reducing the 100,000,000 authorized shares, primarily to support continued Nasdaq listing and increase the per‑share price. As of August 6, 2026, there were 2,011,057 shares outstanding. A separate proposal would allow adjournment of the meeting if needed to secure sufficient votes or a quorum.
Bone Biologics Corporation reported no revenue and a net loss of $1.54 million for the six months ended June 30 2026, an improvement from a $1.76 million loss a year earlier as total operating expenses declined 9.7% to $1.61 million. Research and development spending fell 26.8% to $450,344, largely due to timing of clinical trial activities, while general and administrative costs were roughly flat.
Cash totaled $4.03 million at June 30 2026, down from $5.33 million at year-end, with $1.32 million used in operating activities in the first half. Subsequent to quarter-end, the company completed a July 2026 private placement of pre-funded and common stock warrants, generating approximately $2.7 million in net proceeds and extending expected funding into the second quarter of 2027.
Management and the auditors state that recurring losses, an accumulated deficit of about $89.7 million, and limited capital resources raise substantial doubt about the company’s ability to continue as a going concern without additional financing. The company remains a clinical-stage medical device business focused on its NELL-1/DBM spinal fusion program, with ongoing pilot clinical work in Australia and significant future spending anticipated to support pivotal trials and regulatory approval.
Bone Biologics Corporation is registering up to 6,464,792 shares of common stock for resale by selling stockholders, all issuable upon exercise of outstanding warrants from a July 9, 2026 private placement and related placement agent warrants. The company will not receive proceeds from resale of these shares, but could receive approximately $6.2 million if all warrants are exercised for cash.
Shares outstanding were 1,810,380 as of July 16, 2026 and would be 8,275,172 assuming full warrant exercise. The registered shares equal about 357% of current outstanding stock, and large resales could pressure the share price. Bone Biologics is a clinical-stage medical device company developing NB1, a NELL-1/demineralized bone matrix fusion device for lumbar spinal fusion, with an ongoing pilot study in up to 30 subjects in Australia. The company has a going concern explanatory paragraph in its 2025 audit opinion and relies on additional capital, including potential warrant exercise proceeds, to fund trials, patents, and working capital.
Bone Biologics Corporation provided a mid-2026 shareholder update covering financing, clinical progress and manufacturing readiness for NB1, its rhNELL-1-based bone graft candidate for spinal fusion. In July 2026, the company completed a private placement with a single healthcare-focused institutional investor, generating approximately $3.0 million in gross proceeds before fees.
The financing included Series F and Series G warrants that could deliver up to approximately $6.0 million in additional gross proceeds if fully exercised for cash. Bone Biologics believes this capital extends its operating runway through Q2 2027 to support clinical trials, patent portfolio work and general operations. The company continues its first-in-human NB1 pilot study and expects to complete enrollment by year-end 2026. In May 2026, the validated shelf life of the rhNELL-1 protein was extended to 29 months, supporting manufacturing and supply-chain planning.
Bone Biologics Corporation is registering up to 6,464,792 shares of common stock for resale by existing security holders. All of these shares are issuable upon exercise of outstanding warrants, including 6,338,031 shares tied to a July 9, 2026 private placement and 126,761 placement agent warrant shares. The company will not receive proceeds from any resale of shares by the selling stockholders, but could receive approximately $6.2 million in gross proceeds if all warrants are exercised for cash, at exercise prices ranging from $0.001 to $1.775 per share. Shares outstanding were 1,810,380 as of July 16, 2026; assuming full cash exercise of the registered warrants, shares outstanding would rise to 8,275,172. The company is a clinical-stage medical device developer focused on NELL-1/DBM bone-regeneration products for spinal fusion and other orthopedic uses and currently carries an auditor “going concern” explanatory paragraph, reflecting the need for additional capital to fund operations and clinical trials.
Bone Biologics Corporation postponed its 2026 annual meeting of stockholders, originally set for August 11, 2026, to September 28, 2026 at 11:30 a.m. Eastern Time at its Burlington, Massachusetts offices.
The Board plans to file a Definitive Proxy Statement on Schedule 14A including an additional proposal and concluded more time is needed for stockholders to review materials. The new record date is August 6, 2026, and the deadline for stockholder nominations or other business is July 26, 2026.
Bone Biologics Corporation entered into a private placement with a single institutional investor, raising gross proceeds of approximately $3.0 million and net proceeds of about $2.7 million. The deal includes 2,112,677 pre-funded warrants and accompanying Series F and Series G warrants to purchase up to a total of 6,338,031 shares of common stock at $1.42 per share, subject to ownership caps of 4.99% or 9.99%.
The Series F warrants have a five-year term and the Series G warrants have an 18‑month term, each starting from the later of stockholder approval and effectiveness of a resale registration statement. If all investor warrants are exercised for cash, the Company could receive additional gross proceeds of about $6.0 million. Placement agent H.C. Wainwright & Co. received cash fees, expense reimbursements, and warrants to purchase 126,761 shares. The Company plans to use proceeds for clinical trials, patent portfolio maintenance, working capital, and general corporate purposes.